Clinical evaluation of a quinolone antimicrobial drug, grepafloxacin, for oral use in surgical infection

Nagao Shinagawa, Akihiko Iwai, Yoshitaka Shibata, Keiichi Hori, Yasuo Sawada, Hisashi Okubo, Tsuyoshi Takahashi, Ikuo Hashimoto, Takashi Nakamura, Takashi Hirayama, Kyuya Ishibiki, Toshiharu Furukawa, Takashi Tanaka, Masahiko Kunimatsu, Shigetomi Iwai, Komei Kato, Yoshinobu Sumiyama, Shinya Kusachi, Yoichi Arima, Takeshi AoyagiAkio Nakayoshi, Kazuo Kimura, Osamu Sakurai, Katsuhiko Nohga, Takeaki Shimizu, Osamu Sato, Kazue Ozawa, Taisuke Morimoto, Hiroaki Kinoshita, Ken Morimoto, Shuichi Nakatani, Shoji Kubo, Mikio Fujimoto

Research output: Contribution to journalArticlepeer-review

Abstract

The clinical effects of a newly developed quinolone antimicrobial drug for oral use, grepailoxacin (GPFX), on infectious diseases in the surgical field were investigated by 13 collaborating organizations and 4 related institutions throughout the country. The results were as follows. GPFX was administered to 183 patients at a dose of 150∼400 mg once or twice a day for 3∼14 days. Eight patients were excluded or dropped out, leaving 177 patients to be evaluated for clinical effects. The efficacy rate was 85.9% in the patients with superficial purulent diseases, 66.7% in those with mastitis, 93.8% in those with periproctal abscess, 81.8% in those with secondary infections (19/23 for postoperative wound, 3/3 for wound, 1/1 for burn, and 4/6 for others), and 94.7% in those with cholecystitis and cholangitis. The total efficacy rate was 85.3%. The efficacy rate in 116 patients in whom bacteria were isolated before the start of administration was 85.3%. Eradication of bacteria could be assessed in 99 patients. The isolates were eradicated or superinfection was observed in 83 patients. The eradication rate was 83.8%. The eradication rate in the 170 strains whose eradication was confirmed was 91.7%(11/12 strains) for Staphylococcus aureus, 92.9%(13/14) for coagulase-negative staphylococci, 100%(13/13) for Staphylococcus epidermidis, 73.3%(11/15) for Escherichia coli and 100%(11/11) for Peptostreptococcus spp. The total rate was 86.5%(147/170). With regard to safety, slight and transient adverse reactions, mainly of bitter taste in the oral cavity, were observed in 7 of the 179 subjects. Abnormal change in s-GPT was observed in one patient on clinical laboratory tests. The above results suggest that GPFX is highly useful for infectious diseases in the surgical field.

Original languageEnglish
Pages (from-to)454-467
Number of pages14
JournalJapanese Journal of Chemotherapy
Volume43
DOIs
Publication statusPublished - 1995

Keywords

  • grepafloxacin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clinical evaluation of a quinolone antimicrobial drug, grepafloxacin, for oral use in surgical infection'. Together they form a unique fingerprint.

Cite this